Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 22, p.3582-90 (2010)


2010, Administration, Oral, Aged, Alendronate, Bone Density Conservation Agents, Breast Neoplasms, Center-Authored Paper, Diphosphonates, Female, Humans, Incidence, Middle Aged, Public Health Sciences Division, RISK


Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence.